Anti-Adalimumab Antibodies
Antibodies for bioanalysis and drug monitoring of adalimumab and biosimilars. Develop highly selective and sensitive PK and ADA assays for adalimumab (Humira) using our range of ready-made anti-idiotypic antibodies. Highly specific to adalimumab or the adalimumab-TNFα complex. Fully human surrogate positive control or calibrator. Sequence defined, well characterized reagents with secure supply. Recombinant production, stringent quality control for batch to batch consistency. Non-animal-derived antibodies, reducing the use of animals in science.
Type 1 anti-adalimumab antibodies inhibit the binding of the drug adalimumab to its target, tumor necrosis factor alpha, TNFα. They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. In fully human IgG1 format they are suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.
The Type 3 antibody specifically recognizes the drug-target complex, detecting adalimumab only when it is bound to TNFα. It is suitable as a detection antibody in a PK antigen capture assay.